But it had to be satisfied with the release last week of six million doses of CoronaVac, which was developed by the Chinese lab Sinovac with the Brazilian Butantan Institute in Sao Paulo.
The federally-funded Fiocruz biomedical center in Rio de Janeiro is still awaiting its first shipment of ingredients for AstraZeneca's vaccine, pending Chinese export approval.
President Jair Bolsonaro is under growing pressure to start inoculations in Brazil, which has lost more than 200,000 to COVID-19 - the worst death toll outside the United States.
China has promised to make its vaccines available as a "global public good" as it seeks to counter global criticism for its early handling of the pandemic.
Brazil's health regulator, Anvisa, said late on Monday that the event occurred on Oct. 29 but did not specify if it took place in Brazil or in another country.
Anvisa's decision surprised trial organizers, who said there had been a death but it was unrelated to the vaccine.